KATHERINE Results Back New Adjuvant Standard for HER2+ Breast Cancer

Video
Conference|San Antonio Breast Cancer Symposium (SABCS)

Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.

Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.

Recent Videos
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
3 experts in this video
Related Content
"Policy changes aimed at supporting and more broadly enabling breastfeeding, addressing structural barriers, and promoting a culture shift could reduce overall incidence and racial disparities in TNBC incidence in the [US]," according to the study authors.

Breastfeeding Support May Reduce TNBC Incidence, Mitigate Disparities

Russ Conroy
May 10th 2025
Article

Policy changes supporting breastfeeding may address structural barriers and lower overall incidence and racial disparities surrounding TNBC in the US.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

71 Beyond the Surface: Suspicious Nipple Lesions

71 Beyond the Surface: Suspicious Nipple Lesions

Margarita Riojas Barrett;Logan Healy;Neil Farnsworth;Elizabeth Bonefas;Alastair Thompson;Stacey Carter
May 8th 2025
Article
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?

73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?

Hudhaifah Shaker;Eleanor Rees;Ian J Whitehead;Ansar Farooq;Noaman Sarfraz
May 6th 2025
Article
74 Lessons Learned From a Breast Surgery ERAS Program in an Oncologic Ambulatory Center

74 Lessons Learned From a Breast Surgery ERAS Program in an Oncologic Ambulatory Center

Anoushka Afonso;Joanna Serafin;Tiana Sepahpour;Tracy-Ann Moo;Hanae Tokita
May 5th 2025
Article